Neuralstem Inc., of Rockville, Md., announced the FDA granted orphan drug designation for the treatment of amyotrophic lateral sclerosis (ALS) to its human spinal cord-derived neural stem cells, NSI-566RSC, currently in a Phase I study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.